Investigating brown fat metabolism in people with Type 2 Diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the metabolism of brown adipose tissue (BAT) in individuals with Type 2 Diabetes through cold exposure and advanced imaging techniques. Participants will undergo PET/CT and MRI/MRS imaging to evaluate BAT activity using a new PET tracer, C11-palmitate, which provides a more accurate measure of BAT function compared to previous methods. The study involves three visits, including a screening and two imaging sessions, where participants will receive oral nicotinic acid and experience acute cold exposure to stimulate BAT. The goal is to better understand BAT's role in metabolism and its potential therapeutic implications for Type 2 Diabetes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 10 men and 10 women with T2D.
* 10 non-diabetic men and 10 non-diabetic women (matched for sex, BMI and age to the T2D participants).

Exclusion Criteria:

* Change in weight of more than 2 kg over the past 3 months or recent changes in lifestyle;
* Treatment with a fibrate, thiazolidinedione, insulin, beta-blocker, GLP-1 agonist, or other drug known to affect lipid or carbohydrate metabolism, except statins, metformin, sulfonylurea, DPP-IV inhibitor and other antihypertensive agents that can be temporarily stopped safely prior to the studies, as per our approved protocols;
* Presence of overt cardiovascular, liver, renal or other medical conditions;
* Smoking or consumption of more than 2 alcoholic beverages per day;
* Any other contraindication to temporarily suspending current medications for lipids or hypertension;
* Any contraindication to MRI scanning.
* Having participated to a research study with exposure to radiation in the last two years before the start of the study.

Where it's running

• Centre de recherche du CHUS
  Sherbrooke, Quebec, Canada Recruiting

Study contacts

• Principal investigator: André Carpentier — Université de Sherbrooke
• Study coordinator: Frédérique Frisch
• Email: frederique.frisch@Usherbrooke.ca
• Phone: 819-346-1110

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acute Blood Flow Restriction Walking in Type 2 Diabetes

  This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.

  Recruiting University of British Columbia · Kelowna, British Columbia · NCT07928531

• Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin

  This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.

  Recruiting Medical University of Bialystok · Bialystok · NCT07919236

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

• Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses

  This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.

  Recruiting at 2 sites German Institute of Human Nutrition · Berlin and 1 other locations · NCT07888257

• Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar

  This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.

  Recruiting German Institute of Human Nutrition · Potsdam, Potsdam-Rehbrücke · NCT07868601

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.